Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Novel Dual Chamber Dispenser with polycarbonate and stainless steel components for accurate Rx dosing. More
High yield and low cost protein production in a few days to a couple of weeks (mg or g of protein). Production of proteins, including antibodies, for High-throughput screening assays, antibody generation and structure-activity analyses. More
This method provides an efficient tool for rapid and precise identification of the molecular formula of small molecules, with some characterization of sub-structures, without a cumbersome process of compound isolation. More
This technology is related to optimal conditions for culturing stem cells and feeder cells More
Affimed is interested in working with companies with challenging targets. More
This technology presents key improvements in expression vectors, serum-free media and process of a system for transient gene expression in human cells that have significantly increased the ease and yield of r-protein production. More
Novel carrier proteins for the production of small or large peptides as recombinant fusion proteins. More
Direct thrombin inhibitors designed for improved safety/efficacy profile. Peptide inhibitors suitable for cost-effective recombinant production.Anti-thrombin peptides that can be fused to homing peptides for targeted delivery or fused to markers. More
A pharmaceutical composition comprising HS024 as an active ingredient in an amount effective to protect neuronal cell and to treat or prevent human or mammal suffering from brain diseases such as brain stroke and degenerative brain diseases, together More
A highly metastatic murine breast cancer cell line that provides an excellent mouse model for fundamental as well as therapeutic studies of human breast cancer metastasis. More
Your selection
Browse By
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us